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There is very limited experience regarding the interventional radiological treatment of
adrenocortical cancer (ACC). We present the case of a 57-year-old female patient with a
large, potentially unresectable left-sided ACC and two hepatic metastases. Both liver
tumors were effectively treated by trans-arterial embolization (TAE), followed by TAE of the
bulky primary tumor as a life-saving intervention necessitated by severe intratumoral
bleeding. Surgical removal of the primary tumor revealed complete necrosis. The patient is
considered tumor free after 3.5 years. To the best of our knowledge, this is the first report
to show that even a primary ACC may be completely ablated by selective embolization,
and the fourth to prove the curative potential of liver TAE for ACC metastases. This case
highlights the potential of selective embolization in ACC treatment.
Keywords: adrenocortical cancer, liver metastasis, trans-arterial, embolization, necrosisINTRODUCTION
Adrenocortical cancer (ACC) is a rare malignancy with mostly bad prognosis. Most cases are
diagnosed late, in the presence of distant metastases (1–8). The medical treatment options for ACC
are rather limited, as mitotane is the only available drug specific for the adrenal cortex and its use
associated with severe side effects and a narrow therapeutic range (1). Systemic combination
chemotherapy with EDP protocol (etoposide-doxorubicine-cisplatin) improves survival (2), but the
only hope for cure is still the effective (R0) removal of the tumor and its metastases (3–6). According
to the current clinical practice, the removal of the primary tumor is indicated whenever possible
together with removable oligo-metastases, if R0 seems to be feasible; moreover, excessive hormonal
symptoms might justify a palliative resection in exceptional cases (1–7).
The use of ablative methods other than surgery for ACC are poorly documented in the literature.
Here we present a case, where intraarterial embolization was effectively used both for liver
metastases and a bulky primary tumor leading to complete necrosis and effective surgicaln.org April 2021 | Volume 12 | Article 6771871
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show that an ACC primary tumor may be completely ablated by
selective embolization, together with liver metastases.CASE PRESENTATION
A 57-year-old female patient presented with abdominal
discomfort and 20 kilograms of weight loss without other
specific complaints (body mass index (BMI): 19 kg/m2, serum
albumin 35.5 g/L (normal 35-50)). On physical examination, a
large palpable left upper quadrant non-tender mass was found.
The patient was afebrile and had normal cardiopulmonary
parameters. There were no preexisting chronic diseases in the
medical history, nor were there any potential inherited genetic
disorders in the family. The patient did not take any medications.
Abdominal contrast-enhanced computed tomography (CT)
showed a 20 cm subdiaphragmatic retroperitoneal tumor
together with two metastases in segment 7 (29x21 mm) and
segment 8 (52x43 mm) of the liver (Figure 1A). No lung or bone
metastases were revealed.
The timeline of the case with the most important therapeutic
and diagnostic procedures is shown in Figure 2. The patient was
surgically explored in a non-ACC center in February 2016. A
large, strongly vascularized mass was found in the left
subdiaphragmatic region; the tumor was judged unresectable,
and therefore a fine needle aspiration biopsy (FNAB) sample
was taken. Pathology showed a vimentin+, melan-A+, PanCK +,
S100 –, DOG1 - adrenocortical cancer (Ki67-index was not
defined). Her clinical stage corresponded to ENSAT (European
Network for the Study of Adrenal Tumors) stage IV. There
were no clinical signs of hormone overproduction. Detailed
hormonal investigations showed a mild elevation in 17-OH-
progesterone (310 ng/dL, normal range: 40-250) and dehydro
epiandrosterone sulfate (DHEAS, 385.9 µg/dL, normal range: 130-
330), whereas all cortisol-related laboratory parameters were in
the normal range.
Adjuvant mitotane was initiated, but target level could not be
reached because of serious, mostly gastrointestinal intolerance
symptoms including nausea, severe malaise and diarrhea. EDP
chemotherapy was initiated. The patient was treated with
therapeutic LMWH (low molecular weight heparin) because of
CT-documented portal vein thrombosis. After 4 cycles of EDP,
staging CT in August 2016 showed significant growth in the S8
liver metastasis (d=7 cm) with unchanged primary. To affect
tumor growth, palliative superselective trans-arterial embolization
of both liver metastases was performed with 2 mL 0.1mm PVA
particles through the replaced right hepatic artery arising from the
superior mesenteric artery (Figure 3A). The dominant supplying
artery of the primary tumor was documented, and a second
intervention was scheduled. There were no adverse reactions
following the TAE. However, an unfortunate home accident (6%
second-degree burn) led to an unplanned delay in both medical
and interventional radiological treatments. Soon after recovering
from the skin burn, the patient was transferred to our center inFrontiers in Endocrinology | www.frontiersin.org 2November 2016 with a half-day history of diffuse abdominal
tenderness, back pain, nausea and dizziness; she was seriously
anemic (Hb 25 g/L, normal 120-150)) and showed obvious clinical
signs of hemorrhagic shock. Together with life-saving fluid and
blood resuscitation, CT was performed that showed intratumoral
bleeding in the primary ACC and non-viable liver tumors. To
control bleeding, hyperacute trans-arterial embolization of the
primary tumor was performed with 1 mL 0.2mm PVA particles
through the previously mapped dominant left suprarenal artery
arising from the left inferior phrenic artery (Figure 3B). All the
visceral, renal, and lumbar arteries were cannulated but did not seem
to provide visible arterial supply to the tumor. The bleeding was
stopped. One week later, the patient developed bronchopneumonia
in the lower lobe of the left lung that was effectively treated with
parenteral antibiotics (ceftriaxone), and the patient was stabilized,
but her general condition was considered poor. She remained
hypoalbuminemic after the burns, and her weight continuously
dropped even after discontinuation of mitotane. The patient was
considered to suffer from protein-energy-malnutrition (PEM)
(Malnutrition Universal Screening Tool (9) score 4: high risk,
BMI: 17 kg/m2, albumin 26.5 g/L). By this time, the otherwise
non-tender abdominal mass that was still present on physical
examination started to obviously cause difficulties in eating normal
amounts of solid diet due to local gastric compression. The patient
had severe concerns about a potential second bleeding but did not
feel ready for a second operative exploration, which was mentioned
to and discussed with her after the embolization. High caloric fluid
supplementation diet was administered and prescribed before
discharging her with stabile vital parameters. She was again
referred to the multidisciplinary board of the university after a
control CT in February 2017.
The CT documented a large necrotic mass occupying the
tumor region (Figure 1B). Informed consent was obtained, and
the patient was scheduled for surgical removal of the necrotic
tumor after a planned 6-week-long, partly inpatient
prehabilitation treatment to further reduce PEM. Before the
operation in April 2017, however, a septic condition developed
with a large intra-peritumoral abscess descending down to the left
thigh through the femoral canal (Figure 1C). A left iliac venous
thrombosis was also documented. Being too risky to be operated
acutely, ultrasound-guided drainage of both the femoral (Figure
1D) and retroperitoneal regions (Figure 1E) was performed,
prehabilitation continued, and therapeutic LMWH was again
administered. The patient was stabilized and with repeated
irrigations through the drains, the femoral abscess disappeared
(Figure 1D), and the thrombosis resolved. Together with the
resolution of the septic condition, oral and parenteral calorization,
the patient gradually gained weight (4 kg). After 6 weeks, surgical
re-exploration was performed in June 2017, and the large
retroperitoneal mass was successfully resected together with the
left kidney (R0) (Figure 4). The postoperative course was
uneventful. Pathological result revealed gross tumor necrosis;
only minor patches of non-tumorous suprarenal tissue islands
could be identified. Viable tumor was not found.
The patient has been regularly followed-up since June
2017 (CT or MRI every 3-6 months) without proof of viableApril 2021 | Volume 12 | Article 677187
Huszty et al. Case Report: Embolization of Adrenocortical Cancerresiduum or tumor recurrence. The small S8 scar in the
liver is not growing and considered non-viable. There is
no sign of novel metastasis. The laboratory parameters
including kidney function, liver enzymes and blood count areFrontiers in Endocrinology | www.frontiersin.org 3in the normal range. The patient gained weight (BMI 20) and
feels completely healthy. Adjuvant therapy has not been
initiated any more. At present, the patient can be regarded as
tumor free.FIGURE 1 | CT scan of 20 cm large left adrenocortical carcinoma (*) with segment 8 liver metastasis (†). The segment 7 tumor is not shown on this reconstruction
(A). Necrosis on CT after liver TAE (††) and embolization of the previously bleeding primary tumor (**) (B). Abscess from the necrotic tumor reaching the thigh (+) (C).
Drains in the abscess (arrows); the descending part is already resolved (D, E).April 2021 | Volume 12 | Article 677187
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The biological nature of adrenocortical cancers is heterogeneous.
Known risk factors are age, Ki-67-index, early presence of
metastases, number of affected organs and R0 resection (1, 7).
There is remarkable heterogeneity of individual tumors in the
same stage that is well reflected by the variable survival in the
groups. In a minority of cases, even long-term survival (>60
months) is possible with distant metastases, although the median
survival is only 6-20 months in stage IV (4, 5, 8). Even largeFrontiers in Endocrinology | www.frontiersin.org 4volume oligo-metastases, if resected, have much better prognosis
than multiple small lesions, as the latter are usually poor
candidates for any surgical or ablative therapy (6, 8).
The authors are unsure, whether the primary tumor would
have been really unresectable, if the first attempt was done in a
more experienced center; however, this first unsuccessful surgical
exploration was a key factor in this series of partly unpredictable
events showing that selective embolization of a primary ACC
may lead to complete tumor necrosis. It is also very probable,
that the patient would have later undergone liver resection, hadFIGURE 2 | Timeline of case.FIGURE 3 | Embolization of the S8 tumor through the right replaced hepatic artery was achieved with 0.1mm PVA particles (A). Embolization of the primary tumor
through the left inferior phrenic artery was performed by 0.2mm PVA particles (B). CT, celiac trunk; SA, splenic artery; CHA, common hepatic artery; GDA,
gastroduodenal artery; *, dominant suprarenal artery from left inferior phrenic artery.April 2021 | Volume 12 | Article 677187
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beginning. Going here through a very different path, a
theoretically palliative method was proved to be curative.
Transarterial embolization of liver tumors, mainly hepatocellular
cancers (10), colorectal metastases (11), neuroendocrine tumors
(12), and sometimes others (13) have been routinely practiced
worldwide in the last decades. However, there is limited
experience available regarding adrenal embolization, especially for
ACC. Adrenal embolization may carry some risk of catecholamine
release, but usually only in phaeochromocytoma (14). Most adrenal
embolizations in the literature are reports of sporadic cases of acute
tumoral (mainly phaeochromocytoma, myelolipoma, metastases) or
traumatic bleedings (15), palliative embolizations to reduce
hormone secretion or for pain control (14), preoperative
interventions to reduce vascularity before surgery (16), or more
rarely palliative interventions to control tumor growth (14).
Spontaneous bleeding associated with solid adrenal masses is rare.
The number of reported cases in the literature was 139 till 2012 (17),
and there have been only sporadic cases reported since then (18, 19).
Primary adrenocortical cancer represents a minority among these,
with approximately 7% of all events (17). The number of reported
bleeding tumors largely exceeds the number of documented
embolizations (15, 17): most probably only a minority of all
patients are treated minimally-invasively.
The number of reported primary or locally recurrent ACCs
treated with embolization is 6 in the English literature. O’Keeffe
et al. (14) reported 4 embolizations for unresectable ACCs –
biochemical response was reported, tumor burden was not
documented, significant survival benefit was not achieved. Li et al.
(19) reported a case of a locally recurrent and metastatic (liver,
spleen) ACC, where three sequential embolizations resulted in
partial response and 58 months survival of the patient. Somewhat
similar to our case, a ruptured and bleeding adrenocortical cancerFrontiers in Endocrinology | www.frontiersin.org 5was treated by Kashiwagi et al. (20): embolization of the medial
suprarenal artery was followed by surgical removal of the primary
tumor after 2 months, and a wide necrotic region was documented
in the partially affected tumor.
Treatment of ACC liver metastases should anecdotally have
better results, but such cases are rarely reported. Koh et al. (21)
documented partial remission after embolization of a solitary liver
lesion but no survival benefit. Owen et al. (22) suggested from data
of 6 patients that TACE or SIRT for liver metastases may
contribute to better survival of their patients. Cazejust (23) et al.
achieved stabilization or radiological regression in the majority of
their patients in a larger series of 26 cases, but complete response
was not achieved. However, there are few reports on complete
tumor regression: Soga et al. (24) published two cases with TAE
for solitary metastases, Wong et al. (25) successfully treated a
patient with multiple hepatic tumors with TACE (trans-arterial
chemoembolization), and recently SIRT (selective internal
radiotherapy) was also reported to achieve complete tumor
clearance in a patient with hepatic ACC metastasis (26).
The variable arterial supply of the adrenal gland may limit the
effect of its embolization: each adrenal gland may be supplied
from 3 major arteries arising from the aorta/celiac trunk, renal
artery, subphrenic artery to form a strong plexus under the
capsule (27), but most can be found with catheters. Most
probably, there is no difference among the different types of
embolizing agents for permanent adrenal interventions (15). In
our case, one single dominant artery was documented and
effectively treated, however, malignant tumors may develop
collaterals through tumoral neoangiogenesis that may be
impossible to reach (15). In our case, severe intratumoral
hemorrhage itself may have caused necrosis or altered the
blood flow; however, we think it played only a minor role,
since the dominant artery was mapped and found before theFIGURE 4 | Surgical removal of the necrotic primary tumor together with the left kidney after resolution of the descending abscess. The left renal vein is clamped.April 2021 | Volume 12 | Article 677187
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practically unchanged during the acute procedure. Beyond its
anatomical properties, the biological nature of each individual
tumor, their number, and capacity for embolizing agent uptake
may also determine their potential response to TAE (15, 23). The
value of a single case report, as this one, is always limited by its
unique nature; but the number of embolized ACCs is so low in
the literature, that the potential of this modality, based on our
findings, might be stronger than thought before in this rare
tumor type.
The necrotic areas affected by TAE might become infected.
These events are considered to be rare (0-1%) in terms of liver
tumors, where there is much more documented experience
available (28, 29). Necrotic areas or abscesses may be treated
with drainage and antibiotics effectively in the liver (29, 30).
Regarding the adrenal gland, the organ is routinely removed after
some time in most cases following embolization – most of these
cases include acute bleedings (15) or preoperative devascularizing
procedures (16). However, adrenalectomy will not necessarily be
performed with palliative or traumatic background (14, 15). We
were not aware of any report of adrenal abscess as a consequence of
embolization in the literature. Patients generally do not experience
more than low-grade fever and short-term mild flank pain after
interventions (15). Although the large necrotic area together with
the intratumoral hematoma in our case obviously carried risk of
superinfection, the second surgical attempt was delayed because of
the poor general condition of the patient and her preference.
About two-thirds of patients develop local recurrence or distant
metastases, and most of these tumors are diagnosed in the first two
postoperative years (3–6). The median recurrence-free interval is
around 11 months (6). Follow-up criteria are not rigorously
determined in the current ENSAT guideline or elsewhere (1); we
chose the three months interval for CT or MRI (both
recommended by ENSAT for the diagnosis for ACC) follow-up
to surely not to miss a recurrence in this exceptional case.
In conclusion, we presented that not just liver metastases, but
even a large primary ACC may be effectively treated by arterial
embolization facilitating R0 resection. Based on the many times
proved fact, that R0 resection is the key to survival in ACC, this
example suggests a potentially more important role for
preoperative embolization in ACC not just as a technical
adjunct, but also as a potential method to improve oncologicalFrontiers in Endocrinology | www.frontiersin.org 6efficacy: transarterial embolization may represent an effective
treatment modality in adrenocortical cancer.DATA AVAILABILITY STATEMENT
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